SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
ECCO
An SI Board Since November 2005
Posts SubjectMarks Bans
54 5 0
Emcee:  John McCarthy Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
29Erbitux - Abstract 642: Cetuximab plus oxaliplatin/5-fluorouracil (5-FU)/foliniJohn McCarthy-11/2/2005
28Avastin - Abstract 643: Clinical benefit of bevacizumab in responding and non-rJohn McCarthy-11/2/2005
27Avastin - Abstract 635: Arterial thromboembolic events in a pooled analysis of John McCarthy-11/2/2005
26Avastin - Abstract 629: Starting bevacizumab shortly after venous access deviceJohn McCarthy-11/2/2005
25Avastin - Abstract 602: Preliminary safety of bevacizumab with first-line FOLFOJohn McCarthy-11/2/2005
24Avastin - Abstract 53: HPMA copolymer-TNP-470 (caplostatin) and Avastin show syJohn McCarthy-11/2/2005
23Avastin - Abstract 40: Systemic therapy and novel targeted therapies in renal cJohn McCarthy-11/2/2005
22Avastin - Abstract 1274: Impact of bevacizumab plus 5FU/LV with or without irinJohn McCarthy-11/2/2005
21Avastin - Abstract 117: Novel therapeutic approaches: molecular targeted therapJohn McCarthy-11/2/2005
20Tarceva - Abstract PS6: Kinase inhibitors in cancer: lessons from chronic myeloJohn McCarthy-11/2/2005
19Tarceva - Abstract 649: Erlotinib as single agent in 2nd and 3rd line treatmentJohn McCarthy-11/2/2005
18Tarceva - Abstract 486: Phase II study of erlotinib single agent therapy in recJohn McCarthy-11/2/2005
17Note to myself so that I can remember these words: Tarceva Avastin Tarvacin - John McCarthy-11/2/2005
16VDAs Mouse, rat and clinical studies with the tumour vascular disrupting agent John McCarthy-11/1/2005
15Combining Avastin + TNP-470 Citation: European Journal of Cancer Supplements VoJohn McCarthy-11/1/2005
14Clinical synergism from combinatorial VEGF signal transduction inhibition in patJohn McCarthy-11/1/2005
13Sunitinib malate (SU11248) Citation: European Journal of Cancer Supplements VoJohn McCarthy-11/1/2005
12Alfuzosin Citation: European Journal of Cancer Supplements Volume 3, No. 2, OctJohn McCarthy-11/1/2005
11Patupilone Citation: European Journal of Cancer Supplements Volume 3, No. 2, OcJohn McCarthy-11/1/2005
10Phenoxodiol Citation: European Journal of Cancer Supplements Volume 3, No. 2, John McCarthy-11/1/2005
9Lipoplatin Citation: European Journal of Cancer Supplements Volume 3, No. 2, OcJohn McCarthy-11/1/2005
8Bevacizumab Citation: European Journal of Cancer Supplements Volume 3, No. 2, OJohn McCarthy-11/1/2005
7MPI-0441138 Citation: European Journal of Cancer Supplements Volume 3, No. 2, John McCarthy-11/1/2005
6DO/NDR/02 Citation: European Journal of Cancer Supplements Volume 3, No. 2, OcJohn McCarthy-11/1/2005
5TOCOSOL® Paclitaxel (TP) is Citation: European Journal of Cancer SupplemeJohn McCarthy-11/1/2005
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News